Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia

By              

Experimental and Therapeutic Medicine, Vol. 5, Iss. 3, 2013-01 ,pp. : 982-986

Spandidos Publications

Access to resources Recommend Favorite

Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity

By  

The Oncologist, Vol. 23, Iss. 1, 2018-01 ,pp. : 1-1

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1217-1220

Spandidos Publications

Access to resources Recommend Favorite

Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion

By Czyz Anna  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1123-1126

Humana Press, Inc

Access to resources Recommend Favorite

Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children’s Oncology Group

By Pollack Ian   Hamilton Ronald   Burger Peter   Brat Daniel   Rosenblum Marc   Murdoch Geoffrey   Nikiforova Marina   Holmes Emiko   Zhou Tianni   Cohen Kenneth   Jakacki Regina  

Journal of Neuro-Oncology, Vol. 99, Iss. 2, 2010-09 ,pp. : 155-163

Springer Publishing Company

Access to resources Recommend Favorite